2023-503970-19-00已完成4 期
Randomised, crossover bioequivalence clinical trial of apixabán 5 mg film coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.
Laboratorios Normon S.A.1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2023年3月27日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- AUC0-t
研究概览
简要总结
To evaluate the relative bioavailability of the test formulation of apixaban film-coated tablets compared to the commercial formulations taken as reference and to demonstrate their bioequivalence according to health authorities’ criteria.
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Male or female subjects who, after receiving information about the design, the objectives of the project, the possible risks that could be derived from it and the fact that they can refuse to collaborate at any time, give their written consent to participate in the study.
- •Aged from 18 to
- •No clinically significant organic or psychic conditions.
- •No clinically significant abnormalities in medical records and physical examination.
- •No clinically significant abnormalities in haematology, coagulation, biochemistry, serology (Ag HBs, HC antibodies, HIV antibodies) and urinalysis (see Appendix B).
- •No clinically significant abnormalities in vital signs and electrocardiogram.
排除标准
- •Subjects affected by an organic or psychic condition. Before a volunteer is included, all the safety parameters defined in points 7.3 will be considered. Those who present clinically significant analytical alterations and in whom biochemical kidney and/or liver damage markers are outside the normal range applied by the laboratory will be excluded [GOT, GPT and/or GGT >2.5*ULN and total bilirrubin >1.5*ULN (total bilirrubin >1.5*ULN is acceptable if the direct bilirrubin is <35%)].
- •Participation in another study with administration of investigational drugs in the previous 3 months (if the study was conducted with drug substances marketed in Spain, a period of at least 1 month or 5 half lives, what is longer, will be considered).
- •Inability to follow the instructions or collaborate during the study.
- •History of difficulty in swallowing.
- •Lactose intolerance
- •Subjects who have received prescribed pharmacological treatment in the last 15 days or any kind of medication in the 48 hours prior to receiving the study medication, but women are allowed taking contraceptives. Contraceptive methods must be used at least 4 weeks prior to entry visit and not to be changed for the duration of the study.
- •Subjects with body mass index (weight (kg)/height2 (m2)) outside the 18.5-30.0 range.
- •History of sensitivity to any drug.
- •Positive drug screening (for cannabis, opiates, cocaine and amphetamines).
- •Daily consumers of alcohol and/or acute alcohol poisoning in the last week.
- •Having donated blood in the last month before start of the study.
- •Pregnant or breastfeeding women. Child-bearing age women participating in the study will compromise to use a high effective contraceptive method (see Appendix C) or will be abstinent during their participation in the study.
结局指标
主要结局
AUC0-t
AUC0-t
Cmax
Cmax
次要结局
- AUC0-∞
- Tmax
研究者
Carlos Govantes (R&D Director)
Scientific
Laboratorios Normon S.A.
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Bioequivalence of Apixaban 5 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions.2023-506844-18-00Laboratorios Cinfa S.A.24
招募中
1 期
A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy SubjectsCardiomyopathyNCT07272330Shandong Suncadia Medicine Co., Ltd.38
已完成
1 期
Randomized, crossover, comparative bioavailability study of two Paracetamol-Ibuprofen 25-20 mg/ml oral suspension, administered in single dose to healthy subjects under fasting conditions.2024-519661-22-00Farmalider S.A.24
已完成
1 期
A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy AdultsNCT07261371Pfizer64
已完成
1 期
A study in healthy people to compare 2 different formulations of nerandomilast tablets when taken with or without food2024-511245-18-00Boehringer Ingelheim International GmbH15